Therapeutic Nuclear Drug Market Report 2026

The therapeutic nuclear drug market size has grown rapidly in recent years. It will grow from $2.19 billion in 2025 to $2.51 billion in 2026 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to increasing cancer prevalence, early adoption of iodine-131 in thyroid disorders, limited availability of targeted oncology therapies, growth of nuclear medicine departments, rising clinical acceptance of radiopharmaceuticals.

The therapeutic nuclear drug market size is expected to see rapid growth in the next few years. It will grow to $4.27 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to development of novel therapeutic isotopes, expansion of precision oncology approaches, increasing investment in nuclear medicine infrastructure, growing clinical trials for radioligand therapies, favorable regulatory approvals for targeted nuclear drugs. Major trends in the forecast period include rising adoption of targeted radiopharmaceutical therapies, increasing use of lutetium-177 and alpha-emitting isotopes, growth in cancer-specific nuclear drug applications, expansion of combination therapies with nuclear drugs, strengthening focus on safety dosimetry and regulatory compliance.

The rising prevalence of cancer is anticipated to drive the growth of the therapeutic nuclear drug market in the coming years. Cancer is a disease marked by the uncontrolled growth and spread of abnormal cells. The increasing occurrence of cancer is attributed to factors such as improved detection and diagnostic capabilities, lifestyle-related influences, environmental exposures, and genetic predispositions. Therapeutic nuclear drugs play a crucial role in cancer treatment by offering targeted and effective therapeutic options that help reduce tumor burden, relieve symptoms, and enhance patients’ quality of life. For example, in February 2024, according to the World Health Organization, a Switzerland-based agency of the United Nations, it is projected that more than 35 million new cancer cases will be diagnosed by 2050, representing a 77% increase compared with the estimated 20 million cases recorded in 2022. As a result, the increasing prevalence of cancer is contributing to the growth of the therapeutic nuclear drug market.

Major companies operating in the therapeutic nuclear drug market are advancing targeted radiotherapy solutions by highlighting novel multi-tumor treatment potential through emerging clinical evidence. These initiatives are focused on strengthening innovation pipelines, broadening therapeutic indications, and accelerating the adoption of next-generation radiopharmaceuticals. For instance, in 2025, Actinium Pharmaceuticals, a US-based clinical-stage biopharmaceutical company, released new clinical data for ATNM-400, its first-in-class Actinium-225-based radiotherapy, demonstrating potential efficacy across multiple tumor types, including non-small cell lung cancer (NSCLC). The data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. ATNM-400 is engineered to deliver highly potent alpha-particle therapy with precise targeting, supporting its potential as a transformative treatment platform for a range of solid tumors. This development underscores the industry’s emphasis on expanding the clinical scope of actinium-based radiotherapies to improve patient outcomes and unlock new market opportunities.

In May 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired QSAM Biosciences for an undisclosed amount. Through this acquisition, Telix Pharmaceuticals seeks to strengthen its therapeutic pipeline with the investigational drug Samarium-153-DOTMP, which is designed to target bone metastases and osteosarcoma. QSAM Biosciences is a US-based biotechnology company dedicated to the development of next-generation nuclear therapeutic medicines.

Major companies operating in the therapeutic nuclear drug market are Bayer AG, Novartis International AG, Siemens Healthineers AG, Ipsen S.A., Jubilant DraxImage Inc., Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals.

North America was the largest region in the therapeutic nuclear drug market in 2025. The regions covered in the therapeutic nuclear drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the therapeutic nuclear drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the therapeutic nuclear drug market by increasing costs associated with imported radioactive isotopes, specialized manufacturing equipment, and shielding materials. Hospital-based nuclear medicine departments and cancer research institutes in regions such as North America and Europe are particularly affected due to dependence on cross-border isotope supply chains. These cost pressures can delay treatment availability and raise operational expenses. However, tariffs have also encouraged domestic isotope production, strengthened local supply chains, and stimulated investments in regional nuclear drug manufacturing capabilities.

The therapeutic nuclear drug market research report is one of a series of new reports that provides therapeutic nuclear drug market statistics, including therapeutic nuclear drug industry global market size, regional shares, competitors with a therapeutic nuclear drug market share, detailed therapeutic nuclear drug market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic nuclear drug industry. This therapeutic nuclear drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Therapeutic nuclear drugs are a category of medications that use radioactive substances to treat diseases, especially cancer. These drugs employ targeted radiopharmaceuticals that attach to cancer cells and deliver therapeutic levels of radiation directly to them, helping destroy malignant cells while limiting damage to nearby healthy tissue.

The primary types of therapeutic nuclear drugs include radium-223, lutetium-177, iodine-131, and others. Radium-223 is a therapeutic nuclear drug mainly used for treating prostate cancer that has metastasized to the bones. These drugs are distributed through channels such as hospitals, ambulatory surgical centers, and cancer research institutes, and they are used for applications including thyroid disorders, bone metastasis, lymphoma, and others.

The therapeutic nuclear drug market consists of sales of yttrium-90, actinium-225, bismuth-213, therapeutic iodine-123, and copper-67. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.